This study represents the first systematic attempt to collate estimates of AS prevalence into a single continent-based estimate. In addition, the number of expected cases in Europe and Asia was estimated. Through reviewing the current literature, it is apparent that the continuing conduct of epidemiological studies of AS prevalence is of great importance, particularly as diagnostic capabilities improve and with the recent development of the criteria for axial SpA.

No abstract

Patients with AAV report impaired physical but not mental health. Specifically, fatigue is a principal complaint and appears to be a major determinant of impaired QoL.

No abstract

A new beta-adrenergic receptor blocking agent, ICI.50,172, has been compared with propranolol with respect to the effects on airway resistance (AWR), forced expiratory volume (FEVi) and pulse rate. AWR was measured by body plethysmography. The drugs were given intravenously to ten asthmatic patients on different occasions. ICI.50,172 caused no subjective alteration of their respiratory condition, and only a slight increase in AWR. Propranolol caused dyspnoea and wheeze in all but one of the subjects together with a marked increase in AWR. It is concluded that ICI.50,172 can safely be administered to asthmatic patients and that its introduction could represent an important advance in beta blocking therapy.

No abstract

No abstract

No abstract